Skip to content

    Lung Cancer Health Center

    Font Size

    Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Advanced Malignant Mesothelioma (Stages II, III, and IV)


    In an analysis of all patients who were randomly assigned and treated, the combination of pemetrexed and cisplatin was associated with a statistically significant improvement in survival compared with cisplatin alone; the median survival was 12.1 in the pemetrexed plus cisplatin arm versus 9.3 months in the cisplatin alone arm (P = .020). The hazard ratio for death of patients in the pemetrexed plus cisplatin arm versus those in the control arm was 0.77. Median time-to-progression was significantly longer in the pemetrexed plus cisplatin arm (5.7 months vs. 3.9 months, P = .001). This superiority in the combination arm was also demonstrated in the vitamin-supplemented subgroup. The median survival was 13.3 in the combination arm and 10.0 months in the cisplatin alone arm (P = .051). The principal adverse effects of the pemetrexed plus cisplatin regimen were myelosuppression, fatigue, nausea, vomiting, and dyspnea. Most grade 3 to 4 adverse effects were significantly reduced by vitamin supplementation without any decrease in efficacy.

    A randomized, phase III trial of 250 patients was performed by the European Organisation for Research and Treatment of Cancer (EORTC-08983) to compare cisplatin alone with the combination of raltitrexed, a thymidine synthase inhibitor, and cisplatin in first-line treatment of patients with malignant pleural mesothelioma.[17] Cisplatin (80 mg/m2 IV) was given on day 1, alone or combined with raltitrexed (3 mg/m2). No toxic deaths resulted, and the main grade 3 or 4 toxicities observed were neutropenia and emesis, which were reported twice as often in the combination arm. Among 213 patients with measurable disease, the response rate was 13.6% versus 23.6%, respectively (P = .056). No difference in quality of life was observed. The combination arm was associated with increased survival. Median overall survival was 8.8 months versus 11.4 months, and the 1-year survival rate was 40% versus 46% (P = .048).[17][Level of evidence: 1iiA]

    Malignant Peritoneal Mesothelioma

    A multi-institutional, registry study evaluated cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse, malignant, peritoneal mesothelioma.[18] Among 401 patients, 187 (46%) had complete or near-complete cytoreduction, and 372 (92%) received HIPEC. Of the HIPEC patients, 311 (83%) received cisplatin and doxorubicin. The median follow-up period was 33 months (range, 1-235 months). Grade 3 to 4 complications were seen in 127 (31%) of the 401 patients, and 9 patients (2%) died perioperatively.

    1 | 2 | 3
    Next Article:

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
    Lung Cancer Risks Myths and Facts
    Woman getting ct scan
    Improving Lung Cancer Survival Targeted Therapy
    cancer fighting foods
    Lung Cancer Surprising Differences Between Sexes
    Pets Improve Your Health
    Vitamin D
    Lung Cancer Surgery Options